Biohaven presents BHV-1300 Ph1 SAD data: safe, dose-dependent IgG lowering in 16 subjects

Biohaven Ltd.

16 subjects completed two dosing cohorts; no SAEs, only mild AEs unrelated to drug.
Preliminary dose- and time-dependent IgG lowering observed; IgG1/2/4 reduction greater than IgG3.
BHV-1300 designed to spare IgG3; data consistent with preclinical nonhuman primate models.
Further program update planned at Company's R&D Day on May 29, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.